Intelsat Supports Programmers With Cloud Connect Media
12.4.2022 16:00:00 EEST | Business Wire | Press release
Intelsat — operator of the world’s largest integrated satellite and terrestrial network and a leading provider of inflight connectivity (IFC) — today announced its latest service offering: Cloud Connect Media, a connectivity solution that provides programmers with secure access between the IntelsatOne Media Network and Amazon Web Services (AWS).
Cloud Connect Media is designed to provide content providers with a private, dedicated secure gateway between AWS and the Intelsat global media distribution network. Intelsat is an AWS Select Partner in the AWS Partner Network (APN).
This collaboration can provide Intelsat media customers a more efficient way to connect to their playout, video editing, and additional resources they use in the cloud while still accessing the IntelsatOne media network for centralized distribution and managed services, including uplink and/or downlink to key satellites and teleports, colocation, and much more.
C-SPAN, the nonprofit, public affairs network providing Americans with unfiltered access to federal government proceedings, will be the first Intelsat customer to use Cloud Connect Media to add resiliency and reliability to their linear workflows. C-SPAN and Intelsat have been longstanding partners driving innovation in the media industry, and this trend continues with Cloud Connect Media.
“Intelsat's rollout of Cloud Connect Media helps complete C-SPAN’s transition to a total cloud configuration by providing a fast and reliable path from our uplink location directly to Amazon Web Services, with the most up-to-date connectivity available,” said Roxane Kerr, vice president of Technology for C-SPAN.
“The ability to send and receive media content securely from the cloud, while maintaining broadcast-grade distribution reliability, has become a focus for many of our media customers,” said Bill O’Hara, vice president and general manager of Media Business at Intelsat. “Cloud Connect Media uses AWS to help our customers access their cloud services while still being able to utilize the industry-leading Intelsat network and our full suite of media managed services for regional and global video distribution.”
In addition to advancing media services, Intelsat customers using enterprise and commercial aviation connectivity services who also require dedicated secure connectivity to their cloud-based services will be able to take advantage of AWS Direct Connect.
“AWS Direct Connect can support Intelsat’s mission with a low latency, secure, and private connection to the global AWS network,” said Clint Crosier, director, Aerospace and Satellite at AWS. “The speed and agility of AWS are well suited to help Intelsat meet customer expectations for rapid, reliable global connectivity and communication.”
Cloud Connect Media expands the capabilities of Intelsat’s Cloud Connect, launched in 2020 with secure cloud connectivity available to customers of the global FlexEnterprise network. As organizations continue to integrate cloud-based services into their operations, the Cloud Connect portfolio will aggregate the capabilities of cloud partners and Intelsat’s global networks to enable new services and extend the benefits and reach of the cloud to locations around the globe.
Cloud Connect Media is currently available in the United States and Europe.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.
Follow Us on Social Media:
Twitter | LinkedIn | Facebook | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005361/en/
Contact information
Media:
Melissa Longo
melissa.longo@intelsat.com
+1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom